Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label, Non-Randomized, Multi-Center Study To Assess The Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Intra-Discally in Patients With Degenerative Disc Disease

Next Previous
Search
Trial Profile

An Open Label, Non-Randomized, Multi-Center Study To Assess The Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Intra-Discally in Patients With Degenerative Disc Disease

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 30 Nov 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adipose-derived-autologous-stem-cell-therapy-U.S.-Stem-Cell (Primary)
  • Indications Intervertebral disc degeneration
  • Focus Therapeutic Use
  • Sponsors U.S. Stem Cell

    • Most Recent Events

    • 28 Nov 2017 According to a U.S. Stem Cell media release, data will be presented at the Annual Meeting for International Federation for Adipose Therapeutics and Science (IFATS) 2017.
    • 15 Mar 2017 Status changed from recruiting to completed.
    • 28 Apr 2015 Planned End Date changed from 1 Mar 2016 to 1 Mar 2017 as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top